TY - JOUR
T1 - Age-related and disease-related muscle loss
T2 - The effect of diabetes, obesity, and other diseases
AU - Kalyani, Rita Rastogi
AU - Corriere, Mark
AU - Ferrucci, Luigi
N1 - Funding Information:
The authors are supported by the US National Institute of Diabetes and Digestive and Kidney Diseases ( K23-DK093583, T32-DK062707 ), the Johns Hopkins Older Americans Independence Center ( P30-AG021334 ), and the intramural research programme of the US National Institute on Aging.
Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2014
Y1 - 2014
N2 - The term sarcopenia refers to the loss of muscle mass that occurs with ageing. On the basis of study results showing that muscle mass is only moderately related to functional outcomes, international working groups have proposed that loss of muscle strength or physical function should also be included in the definition. Irrespective of how sarcopenia is defined, both low muscle mass and poor muscle strength are clearly highly prevalent and important risk factors for disability and potentially mortality in individuals as they age. Many chronic diseases, in addition to ageing, could also accelerate decrease of muscle mass and strength, and this effect could be a main underlying mechanism by which chronic diseases cause physical disability. In this Review, we address both age-related and disease-related muscle loss, with a focus on diabetes and obesity but including other disease states, and potential common mechanisms and treatments. Development of treatments for age-related and disease-related muscle loss might improve active life expectancy in older people, and lead to substantial health-care savings and improved quality of life.
AB - The term sarcopenia refers to the loss of muscle mass that occurs with ageing. On the basis of study results showing that muscle mass is only moderately related to functional outcomes, international working groups have proposed that loss of muscle strength or physical function should also be included in the definition. Irrespective of how sarcopenia is defined, both low muscle mass and poor muscle strength are clearly highly prevalent and important risk factors for disability and potentially mortality in individuals as they age. Many chronic diseases, in addition to ageing, could also accelerate decrease of muscle mass and strength, and this effect could be a main underlying mechanism by which chronic diseases cause physical disability. In this Review, we address both age-related and disease-related muscle loss, with a focus on diabetes and obesity but including other disease states, and potential common mechanisms and treatments. Development of treatments for age-related and disease-related muscle loss might improve active life expectancy in older people, and lead to substantial health-care savings and improved quality of life.
UR - http://www.scopus.com/inward/record.url?scp=84911889273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84911889273&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(14)70034-8
DO - 10.1016/S2213-8587(14)70034-8
M3 - Review article
C2 - 24731660
AN - SCOPUS:84911889273
SN - 2213-8587
VL - 2
SP - 819
EP - 829
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 10
ER -